Will Zentalis Pharmaceuticals stock go up?

According to Danelfin AI, Zentalis Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.16%) is +1.35% vs. the average probability (50.82%) of all US-listed stocks.

What is the target price for Zentalis Pharmaceuticals stock?

The Zentalis Pharmaceuticals target price is $7.04 (1Y), according to the average price target offered by analysts.

Is it a good time to buy, sell, or hold Zentalis Pharmaceuticals stock right now?

Zentalis Pharmaceuticals has today a Hold rating (AI Score 5/10), according to Danelfin AI. Its probability of beating the market in 3 months (52.16%) is +1.35% vs. the average probability (50.82%) of all US-listed stocks, based on our AI-powered analysis. You can find more details on whether Zentalis Pharmaceuticals stock is a good buy .

Is Zentalis Pharmaceuticals undervalued right now?

Based on analysts, the average price target upside for Zentalis Pharmaceuticals is +60.89% (1Y). According to Danelfin AI, Zentalis Pharmaceuticals has today an AI Score of 5/10 (Hold Rating).

What was the price range of Zentalis Pharmaceuticals stock over the past 12 months?

The Zentalis Pharmaceuticals stock price range over the past 12 months has been $1.16 - $6.61.

What is going on with Zentalis Pharmaceuticals stock in the last 3 months?

The Zentalis Pharmaceuticals stock performance in the last quarter has been +86.96%.

Does Zentalis Pharmaceuticals offer dividend payments?

No, Zentalis Pharmaceuticals does not currently pay dividends.

What is the current market capitalization of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals's market cap is $310.01M, as of 2026-07-02 08:00.

When is the next ZNTL earnings report date?

ZNTL will publish its next earnings report on 2026-05-12.

Zentalis Pharmaceuticals Inc (ZNTL) AI Stock Analysis

Advanced Chart

Custom range

Jul 2, 2025

→

Jul 2, 2026

Custom range

Jul 2, 2025

→

Jul 2, 2026

ZNTL AI-Powered Stock Analysis

AI Score Explanation

AI Score

Hold

Fundamental
Technical
Sentiment
Low Risk

According to Danelfin’s proprietary AI model, Zentalis Pharmaceuticals Inc today receives an AI Score of 5/10, which translates to a Hold rating. The stock has a 52% probability of outperforming the market in the next 3 months, which is 1% higher than the average probability of any stock (51%). The probability is boosted most significantly by the aggregated impact of fundamental signals not detailed in this report, which adds +2.10%. The company's classification in the Biotechnology industry also positively influences the probability by +0.82%. Conversely, the probability is weighed down by a high Plus Directional Indicator (+DI, 90d) reading, which detracts -0.64%, and a high Beta (a measure of volatility relative to the market), which reduces the probability by -0.61%. Notable data points include the stock's Beta of 1.96, which is in the top 20% of stocks, indicating significantly higher volatility than the market. The stock also shows strong recent performance, with a 6.6% gain on the last trading day, ranking in the top 10%. However, key fundamental metrics are weak, with the most recent quarter's Operating Cash Flow at -$32.96 million and the next quarter's EPS estimate at -$0.48, both in the bottom 10% of stocks. The overall picture is one of a highly volatile biotech stock with mixed signals, where strong technical momentum is offset by weak fundamentals, resulting in a neutral HOLD rating.

AI Score Explanation

Generating AI Score explanation

We're getting the explanation ready so you can easily understand what's behind the AI Score. This may take a few seconds.

AI Score

Hold

Zentalis Pharmaceuticals (ZNTL) has an AI Score of 5/10 (Hold) because, according to an overall analysis, it has a probability advantage of +1.35% of beating the market (S&P500) in the next 3 months. This advantage is calculated as the difference between the average probability of any US-listed stock (50.82%) and the probability of ZNTL (52.16%) of outperforming the market in the next 3 months, as determined by Danelfin AI’s comprehensive analysis.

Average probability of any US-listed stock of beating the market (3M)50.82%
ZNTL probability advantage of beating the market (3M)+1.35%
ZNTL probability of beating the market (3M)52.16%

ZNTL probability advantage of beating the market (3M): +1.35%

The AI-powered overall analysis of Zentalis Pharmaceuticals (ZNTL) is based on the 27 fundamental, technical, and sentiment features that had the greatest impact on stock performance during the last 12 months (alpha signals). These alpha signals explain the probability advantage of ZNTL:

Type	Alpha Signal	Current Value	Value Decile Position	Probability Advantage Impact (3M)
Fundamental	Fundamentals Impact (Long Tail)	-	N/A	+2.10%
Sentiment	Industry (GICS)	Biotechnology	N/A	+0.82%
Technical	Plus Directional Indicator (+DI, 90d)	27.26%		-0.64%
Technical	Beta	1.96		-0.61%
Sentiment	Fear & Greed Index (CNN)	31	N/A	-0.61%
Fundamental	Operating Cash Flow (Qtr Discrete)	-32.96	N/A	+0.57%
Technical	Technicals Impact (Long Tail)	-	N/A	+0.53%
Technical	Alpha Last Day	-0.10%	N/A	+0.49%
Technical	Maximum Volatility	7.78%		-0.43%
Technical	Chart Pattern (252d)	figure_55	N/A	-0.29%
Sentiment	Upgrade to unlock			-0.29%
Technical	Upgrade to unlock			-0.26%
Sentiment	Upgrade to unlock			+0.26%
Fundamental	Upgrade to unlock			+0.24%
Technical	Upgrade to unlock			-0.22%

Rest of Alpha Signals: -0.30%

ZNTL probability advantage of beating the market (3M)Total:+1.35%
ZNTL AI Score

Significant changes Vs previous day

ZNTL Trading Parameters

These suggested trading parameters for a 3-month horizon help improve risk management and decision-making.

Entry:$4.38
Horizon: 3 months
Stop Loss:$XXXXXPro (XXXXXPro) or AI Score < 4/10
Take Profit:$XXXXXPro (XXXXX
Pro
) or AI Score < 4/10

ZNTL Proven Hold Signal & Price Forecast

This is the price chart for ZNTL from January 1, 2026 until today. The chart indicates, in yellow, the 68 days when the stock received a Hold rating (hold signals, AI Score 4 to 6).

Forecast: In the section below, the central dotted line represents the most expected path, while the shaded area indicates the anticipated price range. This is based on previous Hold signals with a 90% confidence level.

Full Track Record

Unlock AI-powered forecast

Closing price (USD)
Hold signals

Forecast:

1 Month
3 Months
6 Months
1 Year

ZNTL Average Past Performance & Win Rate

Three months after its 911 Hold signals since July 2026, ZNTL had an average performance of xxxxxx and a xxxxxx Win rate (positive performance).

911 Past ZNTL Hold Signals	1 Month Later	3 Months Later	6 Months Later	1 Year Later
Average Performance				-34.27%
Average Alpha				-48.99%
Win Rate (% Positive Perf.)				21.07%
% Positive Alpha				15.15%

ZNTL Frequently Asked Questions

Will Zentalis Pharmaceuticals stock go up?
According to Danelfin AI, Zentalis Pharmaceuticals has today an AI Score of 5/10 (Hold rating), because its probability of beating the market in 3 months (52.16%) is +1.35% vs. the average probability (50.82%) of all US-listed stocks.
What is the target price for Zentalis Pharmaceuticals stock?
Is it a good time to buy, sell, or hold Zentalis Pharmaceuticals stock right now?
Is Zentalis Pharmaceuticals undervalued right now?
What was the price range of Zentalis Pharmaceuticals stock over the past 12 months?
What is going on with Zentalis Pharmaceuticals stock in the last 3 months?
Does Zentalis Pharmaceuticals offer dividend payments?
What is the current market capitalization of Zentalis Pharmaceuticals?
When is the next ZNTL earnings report date?

Zentalis Pharmaceuticals Inc Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical enterprise engaged in the discovery and development of small molecule therapies aimed at treating a variety of cancers. Included in their portfolio of candidate products is ZN-c3, an inhibitor aimed at WEE1 - a protein tyrosine kinase used for combating advanced solid tumors and hematological malignancies. It is under various stages of testing including trials focused on uterine serous carcinoma treatment, high-grade serous ovarian cancer related to Cyclin E1, platinum-resistant ovarian cancer, as well as relapsed or refractory osteosarcoma.

Additionally, the versatile use of ZN-c3 extends to combined treatment regimes including those with PARPi for platinum-resistant ovarian cancer, chemotherapy for resistant ovarian conditions as well as pancreatic cancer. The company’s product suite also encompasses ZN-d5, an oral inhibitor targeting B-cell lymphoma 2 for hematological disorders and malignancies; alongside the BCL-xL heterobifunctional degrader which falls under the anti-apoptotic BCL-2 proteins' category intended for solid tumors and hematological malignancies.

Profoundly collaborative, with remarkable licensing agreements with Recurium IP Holdings LLC., Pfizer Inc., Zentera Therapeutics, Dana-Farber and GlaxoSmithKline plc amongst others- Zentalis Pharmaceuticals exemplifies innovation in strategic symbiosis. Incorporated since 2014; this New York City-based company stands tall amongst its peers in both ethos and geographic location.

Sector:Health Care
Country:United States
Industry:Biotechnology
Address:10275 Science Center Drive, Suite 200, San Diego
Employees:106
Website:zentalis.com

Pros

Proprietary drug discovery platform for oncology targets

High switching costs for effective oncology therapies

Potential for market exclusivity via orphan drug designations

Strong intellectual property protection for novel compounds

Addressing unmet medical needs in specific cancer indications

Cons

High capital intensity of preclinical and clinical development

Extensive regulatory approval process for new drug candidates

Binary outcome risk inherent in clinical trial results

Dependency on third-party contract manufacturing organizations

Future reimbursement pressure from healthcare payers

Pros

Cons

Company	AI Score	Compare
ZBIOZenas Biopharma Inc

Company

AI Score

Compare

ZBIOZenas Biopharma Inc

Company

AI Score

Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

	Company	AI Score	Compare
1	COGTCogent Biosciences Inc

Company

AI Score

Compare

COGTCogent Biosciences Inc

Company

AI Score

Compare

ZNTL Stock AI Analysis